InMed Pharmaceuticals (INM) Assets Average (2020 - 2026)

InMed Pharmaceuticals has reported Assets Average for 7 years, with the latest figure at $10.2 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 14.3% year-over-year to $10.2 million; the trailing twelve-month figure through Mar 2026 stood at $10.2 million (up 14.3% YoY), and the FY2025 full-year result was $13.7 million, up 5.68% from the prior year.
• Assets Average for Q1 2026 stood at $10.2 million, down from $12.3 million in the prior quarter.
• The five-year high for Assets Average was $17.4 million in Q1 2022, with the low at $8.9 million in Q1 2025.
• Historically, Assets Average has averaged $13.1 million across 5 years, with a median of $13.1 million in 2023.
• Annual changes were most pronounced in 2022 — Assets Average jumped 44.73% — and 2025, when it sank 37.86%.
• InMed Pharmaceuticals' Assets Average stood at $15.8 million in 2022, then decreased by 16.92% to $13.1 million in 2023, then slipped by 27.53% to $9.5 million in 2024, then rose by 29.45% to $12.3 million in 2025, then decreased by 17.22% to $10.2 million in 2026.
• The last three Assets Average figures came in at $10.2 million (Q1 2026), $12.3 million (Q4 2025), and $14.5 million (Q3 2025), per Business Quant data.